We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+12.64%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$10.5B
AUM Growth
+$891M
Cap. Flow
+$177M
Cap. Flow %
1.69%
Top 10 Hldgs %
36.27%
Holding
147
New
14
Increased
53
Reduced
21
Closed
16

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$98.5M
2
SIEN
Sientra, Inc.
SIEN
+$54.3M
3
GILD icon
Gilead Sciences
GILD
+$50.4M
4
MGLN
Magellan Health Services, Inc.
MGLN
+$47.6M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$42.9M

Top Sells

Rank Stock Value
1
CFN
CAREFUSION CORPORATION
CFN
+$215M
2
A icon
Agilent Technologies
A
+$79M
3
ARWR icon
Arrowhead Research
ARWR
+$76.5M
4
STJ
St Jude Medical
STJ
+$54.8M
5
QGENF
QIAGEN NV
QGENF
+$38.7M

Sector Composition

Rank Sector Weight
1 Healthcare 88.46%
2 Miscellaneous 11.3%
3 Technology 0.16%
4 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQL
101
DELISTED
Arqule Inc
ARQL
$6.96M 0.07%
5,702,000
– –
RGLS
102
DELISTED
Regulus Therapeutics
RGLS
$6.42M 0.06%
+3,333
New +$5.93M
DVA icon
103
DaVita
DVA
$12.1B
$5.76M 0.06%
76,000
+11,000
+17% +$828K
ASPX
104
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
$4.91M 0.05%
+93,600
New +$2.75M
SUPN icon
105
Supernus Pharmaceuticals
SUPN
$2.41B
$4.81M 0.05%
580,000
– –
IPXL
106
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
$4.75M 0.05%
150,000
-100,000
-40% -$2.93M
BSX icon
107
Boston Scientific
BSX
$65.3B
$4.24M 0.04%
320,000
+48,300
+18% +$617K
LUMO
108
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.98M 0.04%
11,111
– –
FATE icon
109
Fate Therapeutics
FATE
$277M
$3.48M 0.03%
692,900
– –
SGEN
110
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
$3.21M 0.03%
+100,000
New +$3.49M
CRIS icon
111
Curis
CRIS
$2.72M
$2.92M 0.03%
975
– –
UPI
112
DELISTED
UROPLASTY INC-NEW
UPI
$2.81M 0.03%
1,363,500
– –
DSCI
113
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$2.79M 0.03%
300,000
– –
CNXR
114
DELISTED
Connecture, Inc.
CNXR
$2.72M 0.03%
+302,300
New +$2.71M
NSPR icon
115
InspireMD
NSPR
$37M
– –
0
– –
ACHN
116
DELISTED
Achillion Pharmaceuticals
ACHN
$1.94M 0.02%
158,000
– –
BLRX
117
BioLineRX
BLRX
$12.2M
$1.84M 0.02%
1,892
– –
SGMO
118
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.52M 0.01%
+100,000
New +$1.21M
XTNT icon
119
Xtant Medical Holdings
XTNT
$46M
$1.44M 0.01%
39,620
– –
CEMP
120
DELISTED
Cempra, Inc.
CEMP
$1.18M 0.01%
+50,000
New +$747K
AMRN
121
Amarin Corp
AMRN
$291M
$392K ﹤0.01%
20,000
– –
ALBO
122
DELISTED
Albireo Pharma Inc
ALBO
$279K ﹤0.01%
6,990
– –
AMGN icon
123
CALL
Amgen
AMGN
$206B
– –
-200,000
Closed -$28.1M
ARWR icon
124
Arrowhead Research
ARWR
$11.4B
– –
-5,178,200
Closed -$76.5M
COO icon
125
CALL
Cooper Companies
COO
$10.3B
– –
-800,000
Closed -$31.1M
2 3 4
5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2014 Portfolio in Review

As of Q4 2014, OrbiMed held 147 positions worth $10.5B, up 9.3% from $9.57B the previous quarter. Its ten largest holdings account for 36% of the portfolio.

OrbiMed's Q4 2014 filing shows 14 new, 53 increased, 21 reduced and 16 closed positions. Its largest new stake was Sientra, Inc.: 318,531 shares worth $53.5M. The largest sale was CAREFUSION CORPORATION, an estimated $215M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Technology.

  • OrbiMed's largest Q4 2014 buy was Sientra, Inc.: 318,531 shares worth $53.5M.
  • OrbiMed added most to Biogen in Q4 2014, an estimated $98.5M increase.
  • OrbiMed's biggest Q4 2014 reduction was Agilent Technologies, cutting an estimated $79M.
  • OrbiMed fully exited CAREFUSION CORPORATION in Q4 2014, selling an estimated $215M.
  • OrbiMed's ten largest holdings make up 36% of its $10.5B portfolio in Q4 2014.
  • OrbiMed opened 14 new positions and closed 16 in Q4 2014.
  • OrbiMed's portfolio value rose 9.3% quarter-over-quarter to $10.5B.

Based on OrbiMed's 13F filing for Q4 2014, filed 13 Feb 2015.